Alabama Joins Nationwide Opioid Settlement, Securing $11.7 Million to Combat Crisis
Funds are in addition to the est. $75 million Alabama is slated to receive from the Sackler family-Purdue Pharma settlement
Alabama Attorney General Steve Marshall today announced that the State is joining a major nationwide settlement with eight pharmaceutical companies tied to the opioid epidemic. With full participation from local governments, public hospitals, and other state agencies, Alabama is set to receive approximately $11.725 million from manufacturers linked to the crisis.
These funds are in addition to the estimated $75 million Alabama is slated to receive from the Sackler family-Purdue Pharma settlement previously reported By ALPolitics.com.
“This settlement marks another pivotal achievement in Alabama’s aggressive and uniquely successful legal strategy to hold opioid manufacturers, distributors, and others accountable,” said AG Marshall. “Our states have faced unimaginable loss due to the widespread abuse and misuse of opioids, and we have responded with decisive legal action.”
The agreement involves eight defendants and spans various payment timelines:
- Mylan (now part of Viatris): $284.4 million over nine years
- Hikma: $95.8 million over one to four years
- Amneal: $71.8 million over ten years
- Apotex: $63.7 million in a single year
- Indivior: $38 million over four years
- Sun: $31 million over one to four years
- Alvogen: $18.7 million in one year
- Zydus: $14.9 million in one year
In addition to direct payments, some companies will provide free pharmaceutical products or cash alternatives. As part of the settlement’s safeguards, seven firms (excluding Indivior) are barred from promoting opioids, creating pills that exceed 40 mg of oxycodone, and must establish systems to flag and report suspicious orders. Indivior has agreed to cease manufacturing opioids for the next decade, though it may continue marketing and selling opioid‑use‑disorder treatments.
Alabama joins numerous other states in the effort to hold drug makers accountable and bolster recovery efforts across communities. The $11.7 million in funds will bolster local health initiatives, strengthen prevention programs, and support treatment services across the state.
